Targeting Solid Tumors & Hematological Malignancies With ADCs Utilizing Auristatin, Topo1i, & Novel Modality Payloads & Dual-Payload ADCs
- Developing a hydrophilic linker with optimized cleavable moiety to enable efficient auristatin, exatecan and novel linker-payloads for ADCs
- Showing DAR4 and DAR MMAU auristatin ADCs with outstanding therapeutic window against solid tumors and hematological malignancies
- Utilizing optimized linker and conjugation technologies for dual-payload ADCs